A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

Anti-CD20 monoclonal antibodies COVID-19 Cladribine Disease-modifying therapy Multiple sclerosis Natalizumab

Journal

Journal of neurology

ISSN: 1432-1459

Titre abrégé: J Neurol

Pays: Germany

ID NLM: 0423161

Informations de publication

Date de publication:
27 Jun 2024

Historique:

received: 04 05 2024

accepted: 10 06 2024

revised: 09 06 2024

medline: 27 6 2024

pubmed: 27 6 2024

entrez: 27 6 2024

Statut: aheadofprint

Résumé

The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset. A multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use. Post-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)]. Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

A multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use.

RESULTS RESULTS

Post-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)].

CONCLUSIONS CONCLUSIONS

Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.

Identifiants

DOI: 10.1007/s00415-024-12518-7 PMID: 38935148

pubmed: 38935148

doi: 10.1007/s00415-024-12518-7

pii: 10.1007/s00415-024-12518-7

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Barzegar M et al (2021) COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm 8:4

doi: 10.1212/NXI.0000000000001001

Leung MW et al (2022) Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Mult Scler 28(11):1808–1818

doi: 10.1177/13524585221094218 pubmed: 35575214 pmcid: 9442628

Chaudhry F et al (2020) COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci 418:117147

doi: 10.1016/j.jns.2020.117147 pubmed: 32980780 pmcid: 7834402

Louapre C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77(9):1079–1088

doi: 10.1001/jamaneurol.2020.2581 pubmed: 32589189

Brownlee W et al (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 94(22):949–952

doi: 10.1212/WNL.0000000000009507 pubmed: 32241953

Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H (2020) Neurological immunotherapy in the era of COVID-19—looking for consensus in the literature. Nat Rev Neurol 16(9):493–505

doi: 10.1038/s41582-020-0385-8 pubmed: 32641860 pmcid: 7341707

Giovannoni G et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073

doi: 10.1016/j.msard.2020.102073 pubmed: 32334820 pmcid: 7138156

Berger JR, Brandstadter R, Bar-Or A (2020) COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm 7:4

doi: 10.1212/NXI.0000000000000761

Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195

doi: 10.1016/j.msard.2020.102195 pubmed: 32460086 pmcid: 7219389

Dalla Costa G et al (2020) Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci 41(7):1647–1650

doi: 10.1007/s10072-020-04519-x pubmed: 32617741 pmcid: 7331489

Januel E et al (2023) Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open 6(6):e2319766–e2319766

doi: 10.1001/jamanetworkopen.2023.19766 pubmed: 37351881 pmcid: 10290250

Schiavetti I et al (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. Multiple Scler Relat Disord 57:103358

doi: 10.1016/j.msard.2021.103358

Bsteh G et al (2022) Has the pandemic changed treatment strategy in multiple sclerosis? Mult Scler Relat Disord 63:103912

doi: 10.1016/j.msard.2022.103912 pubmed: 35636274 pmcid: 9125982

Zaheer R et al (2023) Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis. Mult Scler Relat Disord 71:104575

doi: 10.1016/j.msard.2023.104575 pubmed: 36857853 pmcid: 9924032

Krett JD, Salter A, Newsome SD (2024) Era of COVID-19 in multiple sclerosis care. Neurol Clin 42(1):319–340

doi: 10.1016/j.ncl.2023.06.006 pubmed: 37980121

Thomas W et al (2022) Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study. J Neurol Neurosurg Psychiatry 93(11):1229

doi: 10.1136/jnnp-2021-328340

Sormani MP et al (2021) DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol 8(8):1738–1744

doi: 10.1002/acn3.51408 pubmed: 34240579 pmcid: 8351392

Spelman T et al (2021) Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry. Mult Scler J 28(7):1051–1059

doi: 10.1177/13524585211026272

Zanghì A et al (2022) Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics 19(5):1535–1545

doi: 10.1007/s13311-022-01289-6 pubmed: 36036858 pmcid: 9422942

Bisecco A et al (2024) Covid-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients (P2–6010). Neurology 102(17):6251

doi: 10.1212/WNL.0000000000206347

Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173

doi: 10.1016/S1474-4422(17)30470-2 pubmed: 29275977

Foong YC et al (2024) Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. J Neurol Neurosurg Psychiatry 2:4

Carlini F et al (2023) Cladribine tablets mode of action, learning from the pandemic: a narrative review. Neurol Therapy 12(5):1477–1490

doi: 10.1007/s40120-023-00520-6

Preziosa P et al (2021) COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol 268(8):2697–2699

doi: 10.1007/s00415-020-10309-4 pubmed: 33216223

De Angelis M et al (2020) Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice. Mult Scler Relat Disord 45:102452

doi: 10.1016/j.msard.2020.102452 pubmed: 32823148 pmcid: 7428688

Comi G et al (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 29:168–174

doi: 10.1016/j.msard.2019.01.038 pubmed: 30885375

Chisari CG et al (2021) Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol 21(1):462

doi: 10.1186/s12883-021-02421-3 pubmed: 34839814 pmcid: 8627841

Landi D et al (2022) Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection. Mult Scler Relat Disord 57:103345

doi: 10.1016/j.msard.2021.103345 pubmed: 35158454

Aguirre C et al (2020) Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? Mult Scler Relat Disord 44:102250

doi: 10.1016/j.msard.2020.102250 pubmed: 32531754 pmcid: 7831671

Sigrist CJ, Bridge A, Le Mercier P (2020) A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res 177:104759

doi: 10.1016/j.antiviral.2020.104759 pubmed: 32130973 pmcid: 7114098

Hada M, Mosholder AD, Leishear K, Perez-Vilar S (2022) Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci 43(3):1557–1567

doi: 10.1007/s10072-021-05846-3 pubmed: 35006442 pmcid: 8743352

Simpson-Yap S et al (2021) Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97(19):e1870–e1885

doi: 10.1212/WNL.0000000000012753 pubmed: 34610987 pmcid: 8601210

Arvin AM et al (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72(1):31–39

doi: 10.1001/jamaneurol.2014.3065 pubmed: 25419615 pmcid: 5391035

Luna G et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184–191

doi: 10.1001/jamaneurol.2019.3365 pubmed: 31589278

Barzegar M et al (2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 7:4

doi: 10.1212/NXI.0000000000000753

Sullivan R et al (2021) COVID-19 infection in fingolimod- or siponimod-treated patients: case series. Neurol Neuroimmunol Neuroinflamm 9:1

Teymouri S et al (2023) The effect of Fingolimod on patients with moderate to severe COVID-19. Pharmacol Res Perspect 11(1):e01039

doi: 10.1002/prp2.1039 pubmed: 36567519

Baker D et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149–161

doi: 10.1111/cei.13495 pubmed: 32671831 pmcid: 7405500

Ciotti JR, Valtcheva MV, Cross AH (2020) Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 45:102439

doi: 10.1016/j.msard.2020.102439 pubmed: 32769063 pmcid: 7395588